Pipeline

In order to demonstrate the diversity of the AMR-dedicated SMEs’ pipeline in Europe, the BEAM Alliance has collated its members’ technological assets into a comprehensive portfolio. While its size is already impressive, the proposed categorization approach is further revealing the high level of innovativeness that is being deployed, both at clinical and preclinical stages.

BEAM Infection Curve (BIC)

BEAM Infection Curve (BIC)

Pipeline Rx

Click on column headers to sort the table

memberproductbic*typetargets/indicationsdevelopment
stage
VAXDYNKAPAVAX (VXD-005)1aVaccineCommunity acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Pre-clinical
Spexis AGLptA-OMPTA3aProtein/PeptideComplicated urinary tract infections (cUTI)Lead opt
F2G LtdOlorofim3aNMEAspergillosis refractory, resistant or intolerant to currently available therapy. Infections due to Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species. Treatment of coccidioidomycosis refractory or otherwise unable to be treated with standard of care therapy. Phase II
AdjuTec Pharma ASAPC1483dNMEMBL-CREPre-clinical
Diotheris SASDECOLONIZE1bOtherDecolonization of S.aureus MRDiscovery
Diotheris SASPREVENT1bOtherPrevent infection by S.aureus MRPre-clinical
Aptorum Group LtdALS-33dOtherReviving existing antibiotics to overcome drug ResistanceLead opt
Aptorum Group LtdALS-24aOtherTreatment of bacterial infections casued by Gram Positive Bacteria including Staphylococcus aureus (MRSA)Lead opt
Aptorum Group LtdALS-13aOtherTreatment of viral infections casued by influenza virus ALead opt
Aptorum Group LtdALS-43cOtherTreatment of bacterial infections casued by Staphylococcus aureus infections including MRSAPre-clinical
Debiopharm International1454/S3aNMEHospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
OLGRAMOl20-01Protein/PeptideInfectious relapses Pre-clinical
Selmod GmbHslm 5003aNME Pre-clinical
Selmod GmbHslm 4003aNME Discovery
Selmod GmbHslm 3003aNME Discovery
Selmod GmbHslm 2003aNMEC.C. albicans, flucanozole-resistant; Drug-resistant Aspergillus; Drug-resistant C. aurisLead opt
Selmod GmbHslm 1003aNMEC. albicans, flucanozole-resistant; Drug-resistant Aspergillus; Drug-resistant C. aurisLead opt
BioNTech R&DPM-4773aProtein/PeptideEndolysin specific to bacteria of the genus Gardnerella to treat Bacterial VaginosisLead opt
Nabriva Therapeutics GmbHBC-21263aNMERespiratory tract infections caused by P. aeruginosa, A. baumannii and Burkholderia cepacia complexPre-clinical
Nabriva Therapeutics GmbHBC-70133aNMETopical treatment of skin and skin structure infectionsPhase I
Destiny Pharma plcXF-733aNMEDermal wound infectionsPhase I
AiCuris Anti-infective Cures AGNPI Scaffolds3aNMEUndisclosedDiscovery
AiCuris Anti-infective Cures AGMacrocyles3aNMEUndisclosedDiscovery
Basileaundisclosed3aNMESerious infections in hospitalized patients Lead opt
BasileaNon beta-lactam PBP inhibitor3aNMESerious infections in hospitalized patients Lead opt
Pherecydes PharmaPP11513aPhageMDR infections to Escherichia coliPre-clinical
Pherecydes PharmaPP10023aPhageMDR infections to Escherichia coliPre-clinical
Pherecydes PharmaPP9703aPhageMDR infections to Escherichia coliPre-clinical
Pherecydes PharmaPP9543aPhageMDR infections to Escherichia coliPre-clinical
Pherecydes PharmaPP8143aPhageMDR infections to Escherichia coliPre-clinical
Pherecydes PharmaPP7003aPhageMDR infections to Escherichia coliPre-clinical
Assuré Medical LimitedSol-UTI1bOtherRecurrent Urinary Tract Infection (rUTI)Pre-clinical
BioVersys AGBV1003aNMEA. baumannii (HAP,VAP, BSI)Phase I
Madam Therapeutics BVP103aProtein/PeptideVeterinary Diseases (companion animals and lifestock)Pre-clinical
Destiny Pharma plcDPD-2073aNMEMDR bacterial eye infectionsPre-clinical
AlphanososW9P1543eOtherTuberculosis, Buruli UlcerLead opt
ABAC therapeuticsABAC-40,2443aNMEInfections by MDR/XDR Staph aureusLead opt
ABAC therapeuticsABAC-401053aNMEInfections by MDR/XDR A baumannii, including ColistinR and CarbapenemRLead opt
ANTABIO S.A.SANT33103dNMEHospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter [cUTI, cIAI, Nosocomial Pneumonia]Pre-clinical
VibioSphenSativa3bNMEPulmonary infection, UTIPre-clinical
VAXDYNACINETOVAX (VXD-001)1aVaccineHospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
Summit Therapeutics plcSMT0265713aNMEGonorrhoea infectionPre-clinical
Summit Therapeutics plcRidinilazole3aNMEClostridium difficile infectionPhase III
QureTech Bio ABTIB3aNMETrachoma, Chlamydia eye infectionLead opt
QureTech Bio ABGmP3dNMEVRE and MRSALead opt
QureTech Bio ABCIB3aNMEGenital Chlamydia infectionLead opt
QureTech Bio ABMTI3dNMEMDR TuberculosisPre-clinical
Spexis AGMurepavadin (inhaled)3aProtein/PeptideCystic fibrosis associated infectionsIND/CTA ready
Spexis AGBamA-OMPTA3aProtein/PeptideHospitalacquired or Ventilatoracquired bacterial pneumoniae (HABP/VABP)Lead opt
Phico Therapeutics LtdSASPject™ PT43aOtherSerious Klebsiella Pneumoniae infections where treatment options are limitedPre-clinical
Phico Therapeutics LtdSASPject™ PT53aOtherSerious E.coli infections where treatment options are limitedPre-clinical
Phico Therapeutics LtdSASPject™ PT3.83aOtherSerious Pseudomonas Aeruginosa infections where treatment options are limitedPre-clinical
Pherecydes PharmaPN17773aPhageMDR infections to Pseudomonas aeruginosaPre-clinical
Pherecydes PharmaPN17923aPhageMDR infections to Pseudomonas aeruginosaPre-clinical
Pherecydes PharmaPN17973aPhageMDR infections to Pseudomonas aeruginosaPre-clinical
Pherecydes PharmaPN14933aPhageMDR infections to Staphylococcus aureusPre-clinical
Pherecydes PharmaPN18153aPhageMDR infections to Staphylococcus aureusPre-clinical
Pherecydes PharmaPN19573aPhageMDR infections to Staphylococcus aureusPre-clinical
Pherecydes PharmaPN14503aPhageMDR infections to Pseudomonas aeruginosaPre-clinical
BioNTech R&DPhM3983aPhagePeriprosthetic Joint InfectionsLead opt
BioNTech R&DPhM7543aPhageUrinary Tract InfectionsLead opt
Omnix MedicalOMN63aProtein/PeptideA. baumannii induced Bacteremia or HABP or VABPLead opt
NovaBiotics LtdNovamycin®3aProtein/PeptideInvasive Fungal Disease, mucocutaneous fungal infectionsPre-clinical
NovaBiotics LtdNylexa™3dOtherResistance breakerPre-clinical
NovaBiotics LtdNovarifyn®3aProtein/PeptideGram negative and Gram negative reistant/MDR infections (ESKAPE), some Gram positive coveragePre-clinical
NovaBiotics LtdLuminaderm®1bProtein/PeptideMRSAPre-clinical
NovaBiotics LtdLynovex® inhaled1aOtherCystic FibrosisIND/CTA ready
NovaBiotics LtdNovexatin®3aProtein/PeptideOnychomycosisPhase II
NovaBiotics LtdLynovex® oral3bOtherCystic FibrosisPhase II
NosopharmNOSO-2G3aNMEHospitalacquired or Ventilatoracquired bacterial pneumoniae (HABP/VABP)Lead opt
NosopharmNOSO-5023aNMEComplicated urinary tract infections (cUTI)IND/CTA ready
Northern Antibiotics Oy (Ltd)NAB8153aProtein/PeptidecUTI caused by MDR Gram-negativesPre-clinical
Northern Antibiotics Oy (Ltd)NAB7393aProtein/PeptidecUTI caused by MDR Gram-negativesPre-clinical
Nabriva Therapeutics GmbHLefamulin3aNMEABSSSIPhase II
Nabriva Therapeutics GmbHLefamulin3aNMESTIs, HABP/VABP, Osteomyelitis, Prosthetic Joint InfectionsPre-clinical
Nabriva Therapeutics GmbHLefamulin3aNMEPediatric IndicationsPhase I
Nabriva Therapeutics GmbHLefamulin3aNMECABP (community-acquired bacterial pneumonia)Phase III
Mutabilis SAS2G-DABOCIN3aNMEIV treatment against Enterobacterales & non-fermentersLead opt
Mutabilis SASEBL-14633aNMEIV treatment against EnterobacteralesPre-clinical
Madam Therapeutics BVSAAP1483aProtein/PeptideDiabetic foot ulcers, burns and MRSA carriershipPre-clinical
IMMUNETHEP, SAUnimab3cAntibodyIntensive Care Units / Hospital Acquired infectionsPre-clinical
IMMUNETHEP, SAcPNV1aVaccinePreventivePre-clinical
Hypharm GmbHHY-1331bPhageNasal colonization with MRSAPre-clinical
Helperby Therapeutics LtdHY-0013dOtherUrinary Tract InfectionsPhase II
Helperby Therapeutics LtdHY-0023dOtherIntra-Abdominal InfectionsPhase I
Helperby Therapeutics LtdHY-0041bOtherNasal MRSA decolonisationPhase II
Helperby Therapeutics LtdHY-0053dOtherSkin & Soft Tissue MRSAPhase II
Eligo BioscienceEB0041bOtherMulti-drug resistant EnterobacteriaceaePre-clinical
Destiny Pharma plcXF-733dNMEHospital pneumonia/ventilator-associated pneumonia (VAP)Pre-clinical
Destiny Pharma plcXF-701bNMEBacterial biofilm-infectionsPre-clinical
Destiny Pharma plcXF-731bNMEPrevention of post-surgical infectionPhase II
DEINOVEDNV38373aNMEC.difficile gastrointestinal infectionsPhase II
Debiopharm InternationalDebio 14533aNMEN. gonorrhoeae infectionsLead opt
Debiopharm InternationalAfabicin (Debio 1450)3aNMEABSSSI, Bone & Joint Infections (BJIs)Phase II
Combioxin SACAL024aOtherSevere infectionsPhase II
Centauri Therapeutics LtdABX013cOtherBroad spectrum Gram negative, including clinically-relevant strains of Enterobacteriaceae, P. aeruginosa, and A. baumanniiPre-clinical
Centauri Therapeutics LtdABX023cOtherPseudomonas Aeruginosa specific InhibitorPre-clinical
BioVersys AGBV2004aNMEAnti-toxin for Staphylococcus aureusLead opt
BioVersys AGBV3003aNMEHospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersys AGBVL-GSK0983dNMEAdjuvant reversing resistance and potentiating Ethionamide activity in TuberculosisPhase I
BioFilm PharmaBFP0023eNMEStaphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic FibrosisLead opt
BioFilm PharmaBFP1013eNMEStaphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone InfectionsLead opt
BioFilm PharmaBFP1023eNMEStaphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic FibrosisLead opt
BioFilm PharmaBFP0013eNMEStaphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone InfectionsLead opt
BasileaCeftobiprole3aNMEAcute bacterial skin and skin structure infections, Staphylococcus aureus bacteremiaPhase III
BasileaCeftobiprole3aNMECommunity- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia)Marketed
ANTABIO S.A.SANT_Pei3cNMEPseudomonas infections in Cystic Fibrosis patientsPre-clinical
ANTABIO S.A.SANT26813dNMEHospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) [cUTI, cIAI, Nosocomial Pneumonia]Pre-clinical
AlphanososW16P05763eOtherA. baumannii, P. aeruginosa, MRSA,N. gonorrhoeae, M. tuberculosis - Infectious skin conditions (eczema, acne, sporiasis, ...), difficult woundsPre-clinical
ALLECRA THERAPEUTICSCefepime / Enmetazobactam3dNMEcUTI, cIAI, HAPPhase II
AktheliaHO53/HO56 ADP3cNMEMultidrug resistant lung infections including nosocomial infections (K. pneumoniae)Lead opt
AiCuris Anti-infective Cures AGArtilysins3aProtein/PeptideUndisclosedLead opt
AGILeBiotics B.V.ABX-3953aNMEHospital-treated MDR Gram-negative infectionsLead opt
AGILeBiotics B.V.ABX-605 (Toframicin)3aNMEHospital-treated MDR Gram-negative infectionsPre-clinical
ABAC therapeuticsABAC-39,8773aNMEInfections by MDR/XDR A baumannii, including ColistinR and CarbapenemRPre-clinical
Da VolterraDAV1214bOtherPrevention of gut microbiota antibiotic-dysbiosis and emergence of resistance to β-lactam antibiotics, including carbapenemsLead opt
Da VolterraDAV1324bOtherPrevention of C.difficile infectionsPhase II
PreviousPage 1/12show allNext

*BIC: BEAM Infection Curve

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline Dx

Click on column headers to sort the table

memberkit/testtargeted resultpathogens/indicationslab workflowdevelopment stage
NG BiotechNG-Test Blood Culture PrepAMR Mechanism of Resistance IDEnterobacteriaceae /
Rapid and Direct detection of the major groups of carbapenemases		From isolated colony
LFIA
<30 minutes		CE-IVD and/or FDA 510k
NG BiotechNG-Test MCR-1AMR Mechanism of Resistance IDEnterobacteriaceae /
Detection of colistine resistance		From isolated colony
LFIA
<30 minutes		CE-IVD and/or FDA 510k
NG BiotechNG-Test CTX-M MULTIAMR Mechanism of Resistance IDEnterobacteriaceae /
Detection of the 5 most prevalent ESBL CTX-M Groups (1, 2, 8, 9 and 25)		From isolated colony
LFIA
<30 minutes		CE-IVD and/or FDA 510k
NG BiotechNG-Test CARBA 5AMR Mechanism of Resistance IDEnterobacteriaceae, carbapenem-resistant; 3rd generation cephalosporin-resistant; A. baumannii, carbapenem-resistant; P. aeruginosa, carbapenem-resistant /
Detection and differentiation of KPC, OXA-48, VIM, IMP and NDM		From PBS + Isolated colony
LFIA
<30 minutes		CE-IVD and/or FDA 510k
MeMed Diagnostics Ltd.MeMed COVID-19 Severity™Likelihood of meeting severe outcomePoint-of-need aid to the clinician's stratification of COVID-19 disease severityFrom serum/plasma
 
<30 minutes		CE-IVD and/or FDA 510k
BioFilm ControlAntiBiofilmogram Urinary CareAST PhenotypingE. coli /
Urinary Tract Infections, Catheter Associated Urinary Tract Infections		From isolated colony
Microplate-reader
<4h		Development Phase
BioFilm ControlAntiBiofilmogram Lung CareAST PhenotypingPseudomonas aeruginosa /
Cystic Fibrosis		From isolated colony
Microplate-reader
<4h		Prototype in Lab
BioFilm ControlAntiBiofilmogram Lung CareAST PhenotypingStaphylococcus aureus /
Cystic Fibrosis		From isolated colony
Microplate-reader
<4h		Prototype in Lab
BioFilm ControlAntiBiofilmogram Wound CareAST PhenotypingStaphylococcus aureus /
Diabetic Foot Ulcer, Joint & Bone Infections		From isolated colony
Microplate-reader
<4h		CE-IVD and/or FDA 510k
MeMed Diagnostics Ltd.MeMed BV®Viral vs BacterialPoint-of-need aid to the clinician's discrimination of the viral/bacterial nature of an infectionFrom serum/plasma
 
<30 minutes		CE-IVD and/or FDA 510k
PreviousPage 1/1Next

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.